The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / K••• I•••••••••

O•• R••• C•••••• Partners Sells K••• I••••••••• to L•• G••••

Exit to a strategic buyerannouncedannounced Jul 24, 2023Fact
What happened
Target
K••• I•••••••••
Platform
not an add-on on record
Control
unknown
Share acquired
unknown
Industry
unknown
Target location
CA, US
Seller kind
Sponsor
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
5 named
Buy side
  • L•• G••••Strategic acquirerconfirmed
    “O•• R••• C•••••• Partners Sells K••• I••••••••• to L•• G••••”
  • J••••• G••••••Deal partnerconfirmed
    ““This transaction marks the end of a partnership between K••• and One R•••, during which we worked closely with Nita Moritz and the K••• management team to enhance the company’s leadership in urinalysis and expand its product lineup into toxicology controls,” said J••••• G••••••, Partner at One R•••”
Sell side
  • O•• R••• C••••••Sellerconfirmed
    “O•• R••• C•••••• Partners, LLC (“One R•••” or the “Firm”), a value-oriented, operationally focused private equity firm, today announced that one of its affiliates has completed the sale of K••• I•••••••••, Inc. (“K•••” or the “Company”), a leading developer, manufacturer and marketer of in vitro dia”
Advisory side
  • B••••Sell-side adviserconfirmed
    “B•••• served as financial advisor to K••• on the transaction.”
Side not stated
Evidence
“O•• R••• C•••••• Partners Sells K••• I••••••••• to L•• G••••”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 14, 2026